UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 15, 2016

 

 

Catabasis Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)

 

 

Delaware

 

001-37467

 

26-3687168

(State or Other Jurisdiction
of Incorporation)

 

(Commission File Number)

 

(IRS Employer
Identification No.)

 

One Kendall Square
Bldg. 1400E, Suite B14202
Cambridge, Massachusetts 02139

(Address of Principal Executive Offices)

 

Registrant’s telephone number, including area code: (617) 349-1971

 

None

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

Catabasis Pharmaceuticals, Inc. (the “Company”) held its Annual Meeting of Stockholders on June 15, 2016.  The following is a summary of the matters voted on at that meeting.

 

a)                                     The stockholders of the Company elected Jill C. Milne, Ph.D. and Michael D. Kishbauch as Class I directors to the Company’s Board of Directors, each to serve for a three-year term expiring at the annual meeting of stockholders to be held in 2019.  The results of the stockholders’ vote with respect to the election of Class I directors were as follows:

 

Name

 

Votes For

 

Votes
Withheld

 

Broker Non-
Votes

 

Votes
Abstaining

 

Jill C. Milne, Ph.D.

 

12,947,990

 

157,415

 

945,202

 

—

 

Michael D. Kishbauch

 

13,100,670

 

4,735

 

945,202

 

—

 

 

b)                                     The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016.  The results of the stockholders’ vote with respect to the ratification of such appointment were as follows:

 

Votes For

 

Votes Against

 

Broker Non-Votes

 

Votes Abstaining

 

14,038,278

 

12,329

 

—

 

—

 

 

2


 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

CATABASIS PHARMACEUTICALS, INC.

 

 

 

 

Date: June 20, 2016

By:

/s/ Jill C. Milne

 

 

Jill C. Milne, Ph.D.

 

 

President and Chief Executive Officer

 

3